Rubella Diagnostic Testing Market Report 2026

Rubella Diagnostic Testing Market Overview

• Rubella Diagnostic Testing market size has reached to $1.39 billion in 2025 • Expected to grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: The Rising Cases Of Viral Infections Propelling The Growth Of The Rubella Diagnostic Testing Market • Market Trend: Innovative Solutions In Rubella Diagnostics And Vaccination • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rubella Diagnostic Testing Market?

Rubella diagnostic testing refers to the methods used to detect the presence of rubella virus or antibodies in a patient's blood to confirm if they have been infected with rubella or have immunity against it. These tests help healthcare providers diagnose rubella accurately and manage its implications, especially in vulnerable populations. The main types of diagnostic techniques in rubella diagnostic testing are latex aggregation, liver function tests, enzyme immunoassay (EIA), radioimmunoassay (Ria), fluorescent immunoassay (FIA), and others. Latex agglutination is a diagnostic method where tiny latex beads coated with rubella-specific antigens or antibodies are mixed with a patient’s sample. This technique is applicable across various age groups, including neonates, teenagers, and adults, and serves a range of end users such as hospitals and clinics, cancer diagnostic centers, ambulatory surgical centers, and others.

What Is The Rubella Diagnostic Testing Market Growth Forecast?

The rubella diagnostic testing market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing investments in advanced diagnostic platforms, rising focus on maternal health screening, expansion of automated laboratory testing, growing adoption of point-of-care diagnostics, strengthening of infectious disease surveillance systems. Major trends in the forecast period include increasing adoption of molecular diagnostic techniques, rising use of pcr-based rubella testing, growing demand for prenatal screening, expansion of high-sensitivity immunoassays, enhanced focus on early disease detection.

Global Rubella Diagnostic Testing Market Segmentation

1) By Diagnostic Technique: Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (Ria), Fluorescent Immunoassay (FIA), Other Diagnostic Techniques 2) By Age Group: Neonates, Teenagers, Adults 3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Public Health Laboratories, Other End Users Subsegments: 1) By Latex Agglutination: Qualitative Latex Agglutination Tests, Quantitative Latex Agglutination Tests, Rapid Latex Agglutination Kits 2) By Enzyme Immunoassay (EIA): Direct EIA, Indirect EIA, Sandwich EIA, Competitive EIA 3) By Radioimmunoassay (RIA): Standard RIA, Modified RIA, Single-Antibody RIA 4) By Fluorescent Immunoassay (FIA): Direct FIA, Indirect FIA, Sandwich FIA 5) By Other Diagnostic Techniques: Polymerase Chain Reaction (PCR), Nucleic Acid Amplification Tests (NAAT), Microplate-Based Assays, Western Blotting

What Is The Driver Of The Rubella Diagnostic Testing Market?

The rising cases of viral infections are expected to propel the growth of the rubella diagnostic testing market going forward. Viral infections are illnesses caused by viruses, tiny infectious agents that can only replicate inside the living cells of an organism. The rising cases of viral infections are due to increased global travel, which facilitates the spread of viruses across borders, and climate change, which alters vector habitats and extends the range of disease-carrying organisms. Rubella diagnostic testing helps identify and manage rubella infections early, preventing complications, particularly in pregnant women, and aiding in outbreak control to reduce virus spread. For instance, in December 2023, according to the National Health Service, a UK-based government department, the number of daily hospital admissions for flu averaged 234, marking a 53% increase from the previous week, while hospital cases of norovirus rose by 15% to an average of 406 daily, reflecting a 28% increase from the same week last year. Therefore, the rising cases of viral infections are driving the growth of the rubella diagnostic testing industry.

Key Players In The Global Rubella Diagnostic Testing Market

Major companies operating in the rubella diagnostic testing market are Cardinal Health Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMérieux S.A., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A., Meridian Bioscience Inc., Fortress Diagnostics Ltd., Mylab Discovery Solutions Pvt. Ltd., MP Biomedicals LLC, CTK Biotech Inc., ZEUS Scientific Inc., Creative Diagnostics, Arlington Scientific Inc., AccuBioTech Co. Ltd., Intec Products Inc., Vitrosens Biotechnology Ltd., Sprint Diagnostics Pvt. Ltd., InDevR Inc., Atlas Medical GmbH

Global Rubella Diagnostic Testing Market Trends and Insights

Major companies operating in the rubella diagnostic testing market are focusing on developing innovative solutions, such as a rubella virus vaccine, to enhance diagnostic accuracy and improve preventive measures. The rubella virus vaccine is a vaccine that provides immunity against rubella, often administered as part of the MMR or MMRV combination vaccines to prevent the disease and associated complications. For instance, in March 2023, Merck & Co., Inc., a US-based pharmaceutical company, received FDA approval for the intramuscular (IM) administration of Merck’s M-M-R II vaccine, which is crucial in protecting against rubella, along with measles and mumps. This approval allows healthcare providers to administer the rubella vaccine using the IM route, making it consistent with other routinely recommended pediatric vaccines. Rubella vaccination is essential for preventing outbreaks and protecting against the severe complications the virus can cause, particularly in pregnant women.

What Are Latest Mergers And Acquisitions In The Rubella Diagnostic Testing Market?

In September 2024, Leinco Technologies Inc., a US-based developer of high-purity antibodies, acquired QED Biosciences for an undisclosed amount. Through this acquisition, Leinco Technologies aims to expand its antibody product portfolio and development services, enhancing its life sciences and in vitro diagnostics capabilities while supporting its growth strategy and commitment to innovation and quality for global researchers. QED Biosciences is a US-based developer of novel monoclonal and polyclonal antibody products and offers rubella diagnostic testing services.

Regional Outlook

North America was the largest region in the rubella diagnostic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Rubella Diagnostic Testing Market?

The rubella diagnostic testing market consists of revenues earned by entities by providing services such as serological testing services, serologic tests, molecular diagnostic services, and rapid diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rubella diagnostic testing market also includes sales of serological assays, IgM antibodies, rapid diagnostic tests (RDTs), and polymerase chain reaction (PCR) tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rubella Diagnostic Testing Market Report 2026?

The rubella diagnostic testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rubella diagnostic testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.